A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

October 31, 2024

Conditions

ADHD

Interventions

DRUG

AK0901 capsule

Active Substance: AK0901, Pharmaceutical Form: Capsule, Route of Administration: Oral

DRUG

Placebo

Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral

Trial Locations (2)

Beijing anding hospital capital medical university, Beijing

Peking university sixth hospital, Beijing

All Listed Sponsors

lead

Shanghai Ark Biopharmaceutical Co., Ltd.

INDUSTRY